Form 4: Zentalis Pharmaceuticals CSO Mark Lackner Reports Stock Transactions
SEC Form 4 Filing
Mark Lackner, Chief Scientific Officer of Zentalis Pharmaceuticals, reports acquisition and disposal of common stock and stock options.
Summary
- Mark Lackner, the Chief Scientific Officer of Zentalis Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On February 3, 2025, Lackner acquired 335,907 shares of common stock at $0 and disposed of 14,368 shares at $1.7115.
- Following these transactions, Lackner beneficially owns 512,856 shares of common stock.
- Lackner also acquired 124,714 stock options with an exercise price of $1.68, expiring on February 2, 2035.
- These options vest over four years in substantially equal monthly installments.
- The sale of 14,368 shares was made automatically by the Issuer to cover tax withholding obligations related to vesting restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of earliest transaction: acquisition and disposal of common stock and acquisition of stock options. |
| 02/02/2035 | Expiration date of stock options. |
| 02/05/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Zentalis Pharmaceuticals, Stock Options, Common Stock, Beneficial Ownership, Lackner, ZNTL, Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.